Downregulation of peroxisome proliferator-activated receptor-γ expression in hypertensive atrial fibrillation

Clinical Cardiology

Volumn 32, Issue 6, 2009, Pages 337-345

  Chen, Xiaoping ^a   Bing, Ziyi ^a   He, Jiyun ^a   Jiang, Lingyun ^a   Luo, Xiaojia ^a   Su, Yanling ^a   Kan, Bing ^a   Huang, Dejia ^a   Wei, Yuquan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INTERLEUKIN 1; INTERLEUKIN 6; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; CORRELATION COEFFICIENT; CYTOKINE PRODUCTION; DOWN REGULATION; ENZYME IMMUNOASSAY; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MENTAL CONCENTRATION; MONOCYTE; PATHOGENESIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; ATRIAL FIBRILLATION; CASE-CONTROL STUDIES; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYPERTENSION; INFLAMMATION MEDIATORS; INTERLEUKIN-1; INTERLEUKIN-6; MIDDLE AGED; MONOCYTES; PPAR GAMMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67650559587     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20566     Document Type: Article

References (24)

1. Karthikeyan VJ, Lip GY. White blood cell count and hypertension. J Hum Hypertens. 2006;20:310-312.
2. Bautista LE, Vera LM, Arenas IA, et al. Independent association between inflammatory markers (C-reactive protein, interleukin- 6, and TNF-α) and essential hypertension. J Hum Hypertens. 2005;19:149-154. (Pubitemid 40220638)
3. Psychari SN, Apostolou TS, Sinos L, et al. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol. 2005;95:764-767. (Pubitemid 40340139)
4. Sata N, Hamada N, Horinouchi T, et al. C-reactive protein and atrial fibrillation: is inflammation a consequence or a cause of atrial fibrillation? Jpn Heart J. 2004;45:441-445. (Pubitemid 41518887)
5. Bruins P, te Velthuis H, Yazdanbakhsh AP, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation. 1997;96:3542-3548. (Pubitemid 27513431)
6. Gedikli O, Dogan A, Altuntas I, et al. Inflammatory markers according to types of atrial fibrillation. Int J Cardiol. 2007;120:193-197. (Pubitemid 47042252)
7. Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation. 2001;104:2886-2891. (Pubitemid 33139098)
8. Frustaci A, Chimenti C, Bellocci F, et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997;96:1180-1184. (Pubitemid 27344221)
9. Fajas L, Auboeuf D, Raspe E, et al. The organization, promoter analysis, and expression of the human PPARγ gene. J Biol Chem. 1997;272:18779-18789. (Pubitemid 27318225)
10. Ricote M, Huang J, Fajas L, et al. Expression of the peroxisome proliferator-activated receptor-γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA. 1998;95:7614-7619. (Pubitemid 28293301)
11. Benson S, Wu J, Padmanabhan S, et al. Peroxisome proliferator-activated receptor (PPAR)-γ expression in human vascular smooth muscle cells: inhibition of growth, migration, and cfos expression by the peroxisome proliferator-activated receptor (PPAR)-γ activator troglitazone. Am J Hypertens. 2000;13:74-82. (Pubitemid 30103867)
12. Mehrabi MR, Thalhammer T, Haslmayer P, et al. The peroxisome proliferator-activated receptor gamma (PPARγ) is highly expressed in human heart ventricles. Biomed Pharmacother. 2002;56:407-410. (Pubitemid 35232743)
13. Babaev VR, Yancey PG, Ryzhov SV, et al. Conditional knockout of macrophage PPAR[γ] increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2005;25:1647-1653. (Pubitemid 41098935)
14. Midaoui A, Wu LY, Wang R, et al. Modulation of cardiac and aortic peroxisome proliferator-activated receptor-γ expression by oxidative stress in chronically glucose-fed rats. Am J Hypertens. 2006;19:407-412.
15. Vamecq J, Latruffe N. Medical significance of peroxisome proliferator- activated receptors. Lancet. 1999;354:141-148. (Pubitemid 29313157)
16. Tao L, Liu HR, Gao E, et al. Antioxidative, antinitrative, and vasculoprotective effects of aperoxisome proliferator-activated receptor agonist in hypercholesterolemia. Circulation. 2003;108: 2805-2811. (Pubitemid 37498984)
17. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines: developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114:257-354.
18. Jiang C, Ting AT, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82-86. (Pubitemid 28079219)
19. Kostin S, Klein G, Szalay Z, et al. Structural correlate of atrial fibrillation in human patients. Cardiovasc Res. 2002;54: 361-379. (Pubitemid 34327915)
20. Schotten U, Ausma J, Stellbrink C, et al. Cellular mechanisms of depressed atrial contractility in patients with chronic atrial fibrillation. Circulation. 2001;103:691-698. (Pubitemid 32144198)
21. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005;45:1832-1839. (Pubitemid 40789940)
22. Murray KT, Rottman JN, Arbogast PG, et al. the AFFIRM Investigators. Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM. Heart Rhythm. 2004;1(6): 669-675. (Pubitemid 40028772)
23. Ducharme A, Swedberg K, Pfeffer MA, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J. 2006;152:86-92.
24. Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation. 2002;106:331-336. (Pubitemid 34778957)